ImmunityBio's second quarter product revenue of $50.7M surges 92%, easily beating estimates, while net loss widens.

ImmunityBio reported second quarter 2026 net product revenue of $50.7 million, a 92% increase year-over-year, marking the eighth consecutive quarter of sequential growth for its drug ANKTIVA. The company posted a GAAP net loss of $(0.22) per share, wider than the $(0.10) per share loss in the same period last year, primarily due to non-cash fair value adjustments on liabilities.

Key Highlights

• Second quarter net product revenue from ANKTIVA was $50.7 million, surging 92% year-over-year and substantially beating the $18.5 million consensus estimate.
• Adjusted net loss, a non-GAAP measure, improved to $81.0 million from $89.9 million in the prior-year quarter, driven by higher product revenue.
• The company ended the quarter with a strong liquidity position of $357.4 million in cash, cash equivalents, and marketable securities.